GlaxoSmithKline (NYSE:GSK) stood ready to field questions about its first quarter financial earnings but everyone seemingly wanted to ask CEO Andrew Witty about the pharmaceutical giant’s $2.6 billion ...

And now I would like to hand the call over to Sir Andrew Witty. Andrew Witty Thank you very much. Good afternoon, everybody, and thanks for joining this Q3 2015 results call. We've made further ...

The recent acquisition of Stiefel Laboratories for $3.6bn (see below for details) is the largest so far under GlaxoSmithKline's (GSK) new CEO Andrew Witty and is designed to put the cash rich drug ...

Where the field convenes. Privately. A curated private community for credentialed ethics, risk, and compliance leaders across the ECI and Compliance Week network. Ask the questions you can’t post ...

March 13 (Reuters) - Health insurer UnitedHealth Group Inc on Tuesday named its board member and former GlaxoSmithKline Plc head Andrew Witty as chief executive of its pharmacy benefit unit, Optum, ...

LONDON (Reuters) - GlaxoSmithKline's former chief executive Andrew Witty and its one-time research head Moncef Slaoui both picked up new jobs in the biotech venture capital sector on Tuesday, ...

The National Institute for Health and Clinical Excellence (NICE), the UK's health technology assessment (HTA) body, fired back against GlaxoSmithKline (GSK) CEO Andrew Witty after he remarked that the ...

Andrew Witty, the chief executive of pharmaceutical manufacturer GlakoSmithKline, said in an interview with the BBC on 25 February he believes the UK's National Institute for Health and Clinical ...

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in ...

DAVOS, Switzerland (Reuters) - GlaxoSmithKline's chief executive, under pressure from some investors to break up the group, said on Thursday the drugmaker's large consumer healthcare unit had the ...

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in ...

It's been roughly four weeks since U.K.-based pharmaceutical giant GlaxoSmithKline reported mixed results for the fourth quarter, and investors still aren't sure what to make of its performance.